Targeting adenosine mediated immunosuppression to enhance CAR T cell activity

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1122444

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The use of white blood cells genetically engineered to eradicate cancer cells specifically has been a major breakthrough in cancer treatment. These cells (CAR T cells) are very effective in blood cancers, but do not currently work well in other cancers. This is due to the immune suppressing nature of the cancer environment. I propose to use strategies to overcome this by genetically reprogramming the CAR T cells to be resistant to suppression by the cancer and therefore be more effective.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2019

Funding Scheme: Project Grants

Funding Amount: $633,447.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Tumour Immunology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

T cell activation | T cell immunotherapy | adenosine | adenosine receptors | tumour immunotherapy

Related Links